BioCentury | Jan 23, 2021
Politics, Policy & Law

Biden memo freezes sunsets

The Biden administration has set wheels in motion to evaluate and possibly reverse a series of maneuvers imposed by the Trump administration that limited FDA’s authority, reduced its ability to function, and exposed career staff...
BioCentury | Jan 23, 2021
Finance

2020’s most active biotech VCs: Data Byte

OrbiMed Advisors continued to lead the pack in terms of number of biotech VC investments made in 2020, followed by RA Capital and Cormorant.  According to BioCentury’s BCIQ database, the top 50 VCs by number...
BioCentury | Jan 23, 2021
Emerging Company Profile

Technology showcase: BioCentury’s 2020 class of emerging companies

As emerging therapeutic modalities move toward mainstream, a flood of new companies has arisen to break through the limitations of first-generation technologies and expand the reach of gene and cell therapies,...
BioCentury | Jan 21, 2021
Deals

Jan. 21 Quick Takes: Plexium extends series A, adds Grey as chair; plus Immunotech-T-Cure, Turnstone, reMYND, Gritstone-Genevant, Mitsubishi Tanabe-Aquestive, Mitsubishi Tanabe-Takeda

Preclinical protein degradation play Plexium Inc. raised $35 million in an extension of its series A round and appointed Mike Grey as chairman. The financing, led by Lux Capital and Pivotal BioVentures,...
BioCentury | Jan 21, 2021
Product Development

The evolving zeitgeist of COVID-19 testing

Becoming an essential pillar of the pandemic response has pushed the diagnostics industry toward more rapid and decentralized technologies, with a greater focus on routine asymptomatic screening. One year...
BioCentury | Jan 21, 2021
Deals

Jan. 20 Quick Takes: Beam adds $260M; plus Lilly-Merus, Thermo Fisher-Mesa, Verve, Aclaris, ViGeneron-Daiichi Sankyo

Crossover investors supplied Beam Therapeutics Inc. (NASDAQ:BEAM) with $260 million in a private placement early Tuesday, purchasing 2.8 million shares at $93. The price is an 18% discount to Beam’s closing price Friday of $113.04....
BioCentury | Jan 21, 2021
Management Tracks

MacDonald to succeed retiring Ostrach as Dynavax CFO; plus Antibiotic Resistance UK, Arix, Viridian, Avrobio, Imago, ONL, Atea, Chiasma, Tiziana, Elevar,  and Imara

Dynavax Technologies Corp. (NASDAQ:DVAX) hired Kelly MacDonald as SVP and CFO, effective March 1. She succeeds CFO Michael Ostrach, who is retiring after 14 years and will remain with the vaccine company as an adviser. MacDonald was...
BioCentury | Jan 20, 2021
Product Development

Trucode reboots as Vera with Abingworth-led $80M series C, disease-modifying therapy for orphan kidney disease

Sixteen months after it emerged from stealth, Trucode has moved on from gene editing and relaunched as Vera with an Abingworth-led $80 million series C round to build an in-licensed portfolio of autoimmune assets. First up for the...
BioCentury | Jan 16, 2021
Politics, Policy & Law

Woodcock’s appointment as acting FDA commissioner could be audition for permanent position

Politics, Policy & Law When Janet Woodcock moves into the FDA commissioner’s office next week, she will take charge, at least on an acting basis, of an agency that has been pummeled for months. President...
BioCentury | Jan 16, 2021
Product Development

Jan. 15 Quick Takes: Darzalex gains first FDA approval for form of amyloidosis; plus Thermo Fisher, Lilly, DBV, Dr. Reddy’s, Alexion, Taiho, Astellas-Actinium

FDA granted accelerated approval to Darzalex Faspro daratumumab/hyaluronidase-fihj from Johnson & Johnson (NYSE:JNJ) and Genmab A/S (CSE:GMAB; NASDAQ:GMAB) to treat newly diagnosed light-chain amyloidosis. It is the first and only therapy for the indication, according to Genmab,...
Items per page:
1 - 10 of 14170
BioCentury | Jan 23, 2021
Politics, Policy & Law

Biden memo freezes sunsets

The Biden administration has set wheels in motion to evaluate and possibly reverse a series of maneuvers imposed by the Trump administration that limited FDA’s authority, reduced its ability to function, and exposed career staff...
BioCentury | Jan 23, 2021
Finance

2020’s most active biotech VCs: Data Byte

OrbiMed Advisors continued to lead the pack in terms of number of biotech VC investments made in 2020, followed by RA Capital and Cormorant.  According to BioCentury’s BCIQ database, the top 50 VCs by number...
BioCentury | Jan 23, 2021
Emerging Company Profile

Technology showcase: BioCentury’s 2020 class of emerging companies

As emerging therapeutic modalities move toward mainstream, a flood of new companies has arisen to break through the limitations of first-generation technologies and expand the reach of gene and cell therapies,...
BioCentury | Jan 21, 2021
Deals

Jan. 21 Quick Takes: Plexium extends series A, adds Grey as chair; plus Immunotech-T-Cure, Turnstone, reMYND, Gritstone-Genevant, Mitsubishi Tanabe-Aquestive, Mitsubishi Tanabe-Takeda

Preclinical protein degradation play Plexium Inc. raised $35 million in an extension of its series A round and appointed Mike Grey as chairman. The financing, led by Lux Capital and Pivotal BioVentures,...
BioCentury | Jan 21, 2021
Product Development

The evolving zeitgeist of COVID-19 testing

Becoming an essential pillar of the pandemic response has pushed the diagnostics industry toward more rapid and decentralized technologies, with a greater focus on routine asymptomatic screening. One year...
BioCentury | Jan 21, 2021
Deals

Jan. 20 Quick Takes: Beam adds $260M; plus Lilly-Merus, Thermo Fisher-Mesa, Verve, Aclaris, ViGeneron-Daiichi Sankyo

Crossover investors supplied Beam Therapeutics Inc. (NASDAQ:BEAM) with $260 million in a private placement early Tuesday, purchasing 2.8 million shares at $93. The price is an 18% discount to Beam’s closing price Friday of $113.04....
BioCentury | Jan 21, 2021
Management Tracks

MacDonald to succeed retiring Ostrach as Dynavax CFO; plus Antibiotic Resistance UK, Arix, Viridian, Avrobio, Imago, ONL, Atea, Chiasma, Tiziana, Elevar,  and Imara

Dynavax Technologies Corp. (NASDAQ:DVAX) hired Kelly MacDonald as SVP and CFO, effective March 1. She succeeds CFO Michael Ostrach, who is retiring after 14 years and will remain with the vaccine company as an adviser. MacDonald was...
BioCentury | Jan 20, 2021
Product Development

Trucode reboots as Vera with Abingworth-led $80M series C, disease-modifying therapy for orphan kidney disease

Sixteen months after it emerged from stealth, Trucode has moved on from gene editing and relaunched as Vera with an Abingworth-led $80 million series C round to build an in-licensed portfolio of autoimmune assets. First up for the...
BioCentury | Jan 16, 2021
Politics, Policy & Law

Woodcock’s appointment as acting FDA commissioner could be audition for permanent position

Politics, Policy & Law When Janet Woodcock moves into the FDA commissioner’s office next week, she will take charge, at least on an acting basis, of an agency that has been pummeled for months. President...
BioCentury | Jan 16, 2021
Product Development

Jan. 15 Quick Takes: Darzalex gains first FDA approval for form of amyloidosis; plus Thermo Fisher, Lilly, DBV, Dr. Reddy’s, Alexion, Taiho, Astellas-Actinium

FDA granted accelerated approval to Darzalex Faspro daratumumab/hyaluronidase-fihj from Johnson & Johnson (NYSE:JNJ) and Genmab A/S (CSE:GMAB; NASDAQ:GMAB) to treat newly diagnosed light-chain amyloidosis. It is the first and only therapy for the indication, according to Genmab,...
Items per page:
1 - 10 of 14170